M-MuLV Reverse Transcriptase

來源: 發(fā)布時(shí)間:2024-04-27

透明質(zhì)酸酶活力單位(Unitdefinition)基于USP透明質(zhì)酸酶參照標(biāo)準(zhǔn),即每分鐘在37℃,pH5.7的2mL反應(yīng)液中引起OD6000.330個(gè)變化定義為一個(gè)活力單位。抑制劑(Inhibitor)Fe2+,F(xiàn)e3+,Zn2+,Cu2+,肝素,金精三羧酸,硫酸,硝酸,乙?;该髻|(zhì)酸,硫酸纖維素酯,膽汁等結(jié)構(gòu)式(Structure)運(yùn)輸和保存方法冰袋運(yùn)輸。-20℃保存,兩年有效。溶液配制溶于0.02MPBS(pH7.0),含77mMNaCl和0.01%BSA,濃度為1mg/mL。現(xiàn)配現(xiàn)用。該產(chǎn)品儲(chǔ)存液不穩(wěn)定,使用時(shí)建議現(xiàn)配現(xiàn)用。為了您的安全和健康,請(qǐng)穿實(shí)驗(yàn)服并戴一次性手套操作。RANTES是CC趨化因子,可以通過CCR1,CCR3,CCR5和US28(巨細(xì)胞病毒受體)受體發(fā)出信號(hào)。M-MuLV Reverse Transcriptase

M-MuLV Reverse Transcriptase,標(biāo)準(zhǔn)物質(zhì)

Recombinant Human ACE2/ACEH Protein,hFc Tag性能參數(shù),分子別名(Synonyms)ACE2;ACEH;ACE-2表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)HumanACE2/ACEHProteinisexpressedfromHEK293withhFctagattheC-Terminus.ItcontainsGln18-Ser740.[Accession|Q9BYF1-1]分子量大?。∕olecularWeight)TheproteinhasapredictedMWof109.2kDa.Duetoglycosylation,theproteinmigratesto115-130kDabasedonSDS-PAGEresult.Endotoxin)Lessthan1EUperμgbytheLALmethod.純度(Purity)>95%asdeterminedbySDS-PAGEandHPLC.活性(Activity)ELISAData:ImmobilizedSARS-COV-2SpikeS(B.1.1.529/Omicron)Trimer,HisTagat1μg/ml(100μl/well)ontheplate.DoseresponsecurveforHumanACE2,hFcTagwiththeEC50of13.7ng/mldeterminedbyELISA.制劑(Formulation)Lyophilizedfrom0.22μmfilteredsolutioninPBS(pH7.4).Normally8%trehaloseisaddedasprotectantbeforelyophilization.重構(gòu)方法(Reconstitution)Centrifugethetubebeforeopening.Reconstitutingtoaconcentrationmorethan100μg/mlisrecommended.Dissolvethelyophilizedproteinindistilledwater.Recombinant Canine LRRC15/LIB Protein,His Tag然而,在肝臟中,IL-28A誘導(dǎo)的Th1細(xì)胞因子反應(yīng)有助于T細(xì)胞介導(dǎo)的肝炎的炎癥。

M-MuLV Reverse Transcriptase,標(biāo)準(zhǔn)物質(zhì)

α-凝血酶(α-Thrombin)產(chǎn)品性質(zhì)中文別名(Chinesesynonym)α-凝血酶;IIa因子;英文別名(Englishsynonym)α-Thrombin;FactorIIaCAS號(hào)(CASNO.)9002-04-4分子量(Molecularweight)37000daltons活力(Activity)≥3091.00NIHU/mg緩沖液組分(Buffer)50mMSodiumCitrate/0.2MNaCl/0.1%PEG-8000/pH6.5含量(Totalprotein)0.324mg運(yùn)輸和保存方法粉末冰袋運(yùn)輸,2-8℃保存;配好的液體,請(qǐng)于≤-60℃保存。使用方法(酶切體系)產(chǎn)品溶于水,配成的1000U/ml儲(chǔ)存液,根據(jù)使用量分配于不同的離心管中,凍存于?20℃保存,凝血酶對(duì)不同的融合蛋白切割效率是不一樣的,首先要進(jìn)行小量切割試驗(yàn)。比如固定融合蛋白10ug,加不同量的凝血酶(如0.1U,0.2U,0.5U,1U等),在不同的溫度(如4度,16度,室溫或37度等)下進(jìn)行試驗(yàn)。

透明質(zhì)酸酶,英文名稱Hyaluronidase,一類能夠降低體內(nèi)透明質(zhì)酸活性的酶的總稱,結(jié)構(gòu)上由4個(gè)相同亞基構(gòu)成,每個(gè)亞基分子量接近14kDa,該酶是一種糖蛋白,包含5%的甘露糖和2.2%的葡萄糖胺。功能上該酶可隨機(jī)裂解透明質(zhì)酸、軟骨素和硫酸軟骨素中的β-N-乙酰己糖胺-[1→4]糖苷鍵。常與膠原酶聯(lián)合使用于降解細(xì)胞外基質(zhì),從而從組織中分離活細(xì)胞。本品來源于牛睪丸,活力值為400–1,000units/mg,合適的pH值為4.5–6.0。產(chǎn)品性質(zhì)中文別名(ChineseSynonym)玻璃糖醛酸酶;玻璃酸酶英文別名(EnglishSynonym)Hyaluronoglucosaminidase;Hyaluronate4-glycanohydrolaseCAS號(hào)(CASNO.)37326-33-3來源(Source)牛睪丸分子量(MolecularWeight)~55kDa類型(Type)I-S外觀(Appearance)淡黃色至米黃色至褐色粉末UbcH3還有兩個(gè)泛素結(jié)合位點(diǎn)UBS1(來自aa 205-215)和UBS2(來自aa 216-225),以及一個(gè)c端酸性尾部結(jié)構(gòu)域。

M-MuLV Reverse Transcriptase,標(biāo)準(zhǔn)物質(zhì)

PE-labeled Human HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Tetramer Protein,His-Avi Tag性能參數(shù)表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)PE-labeledHumanHLA-A*02:01&B2M&P53R175H(HMTEVVRHC)TetramerProteinisexpressedfromHEK293withHistagandAvitagattheC-Terminus.PE-labeledHumanHLA-A*02:01&B2M&P53R175H(HMTEVVRHC)TetramerisassembledbybiotinylatedmonomerandPE-labeledstreptavidin.ItcontainsGly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)andHMTEVVRHCpeptide.(Endotoxin)Lessthan1EUperμgbytheLALmethod.制劑(Formulation)Suppliedas0.22μmfilteredsolutionin20mMPB,500mMNaCl,0.2%BSA(pH8.0).儲(chǔ)存條件Theproductshouldbestoredat-85~-65℃for3monthfromdateofreceipt.Recommendtoaliquottheproteinintosmallerquantitieswhenfirstusedandavoidrepeatedfreeze-thawcycles.RANTES還具有抑制某些HIV-1,HIV-2和Simian免疫缺陷病毒(SIV)的菌株的能力。Recombinant Mouse NKG2C/CD159c Protein,hFc Tag

重組腸激酶為采用重組大腸桿菌分泌表達(dá)的高純度、高活性、高特異的牛腸激酶,不含其他蛋白酶。M-MuLV Reverse Transcriptase

SARS-CoV-2,whichcausestheglobalpandemiccoronavirusdisease2019(Covid-19),belongstoafamilyofvirusesknownascoronaviruses.TheSARS-CoV-2Sproteinisaglycoproteinthatmediatesmembranefusionandviralentry.TheRBDofSARS-CoV-2bindsametallopeptidase,angiotensin-convertingenzyme2(ACE-2).SeveralemergingSARS-CoV-2genomeshavebeenidentifiedincludingtheOmicron,orB.1.1.529,variant.FirstidentifiedinNovember2021inSouthAfrica,theOmicronvariantquicklybecamethepredominantSARS-CoV-2variantandisconsideredavariantofconcern(VOC).TheOmicronvariantcontains15mutationsinRBDdomainthatpotentiallyaffectviralfitnessandtransmissibility.ThemajorityofthemutationsareinvolvedinACE-2bindingandOmicronbindsACE-2withgreateraffinity,potentiallyexplainingitsincreasedtransmissibility.Severalofthesemutationsarealsoidentifiedinfacilitatingimmuneescapeandreducingneutralizationactivitytoseveralmonoclonalantibodies.M-MuLV Reverse Transcriptase